Rafferty Asset Management, LLC Ocugen, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Ocugen, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 797,331 shares of OCGN stock, worth $677,731. This represents 0.0% of its overall portfolio holdings.

Number of Shares

797,331

Previous 1,077,042 25.97%

Holding current value

$677,731

Previous $1.67 Million 52.73%

% of portfolio

0.0%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.98 - $1.95 $274,116 - $545,436	-279,711 Reduced 25.97%	797,331 $789,000
Q2 2024 Aug 13, 2024	BUY	$1.18 - $1.98 $1.27 Million - $2.13 Million	1,077,042 New	1,077,042 $1.67 Million
Q4 2022 Feb 13, 2023	BUY	$1.11 - $1.87 $596,361 - $1 Million	537,263 Added 27.78%	2,471,170 $3.21 Million
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $959,302 - $1.7 Million	548,173 Added 39.56%	1,933,907 $3.44 Million
Q2 2022 Aug 12, 2022	SELL	$1.83 - $3.45 $1.46 Million - $2.75 Million	-796,766 Reduced 36.51%	1,385,734 $3.15 Million
Q1 2022 May 13, 2022	BUY	$2.34 - $4.72 $2.8 Million - $5.65 Million	1,196,855 Added 121.43%	2,182,500 $7.2 Million
Q4 2021 Feb 10, 2022	BUY	$4.38 - $15.67 $2.41 Million - $8.62 Million	549,841 Added 126.17%	985,645 $4.49 Million
Q3 2021 Nov 10, 2021	BUY	$6.36 - $8.51 $154,999 - $207,397	24,371 Added 5.92%	435,804 $3.13 Million
Q2 2021 Aug 10, 2021	BUY	$5.52 - $15.68 $431,951 - $1.23 Million	78,252 Added 23.49%	411,433 $3.3 Million
Q1 2021 May 10, 2021	BUY	$1.66 - $15.81 $553,080 - $5.27 Million	333,181 New	333,181 $2.26 Million

Others Institutions Holding OCGN

# of Institutions

124

Shares Held

78.3M

Call Options Held

535K

Put Options Held

523K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $184M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Ocugen, Inc. Transaction History